TABLE 5.
Immunoreactivity of recombinant SET proteins with human patient sera by Western blot analysis
Patient serum samplea | Reactivity of recombinant SET proteinb
|
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
SET1 | SET2 | SET3 | SET4 | SET5 | SET6 | SET7 | SET8 | SET9 | SET10 | SET11 | |
1a | + | + | + | + | + | ||||||
1c | + | + | + | + | + | ||||||
2a | + | + | + | ||||||||
2c | + | + | + | ||||||||
3a | + | ||||||||||
3c | + | + | + | ||||||||
4a | + | ||||||||||
4c | + | + | + | ||||||||
5a | + | ||||||||||
5c | + | ||||||||||
6a | + | + | |||||||||
6c | + | + | |||||||||
7a | |||||||||||
7c | + | ||||||||||
8a | + | + | + | + | + | ||||||
8c | + | + | + | + | + | + | |||||
9a | + | + | |||||||||
9c | + | + | + | + | |||||||
10a | + | ||||||||||
10c | + | + | |||||||||
91a | + | ||||||||||
91c | + | + | |||||||||
92a | + | + | + | ||||||||
92c | + | + | + | ||||||||
93a | + | + | |||||||||
93c | + | + | + | ||||||||
94a | |||||||||||
94c | + | ||||||||||
96a | + | ||||||||||
96c | + | ||||||||||
97a | + | + | + | ||||||||
97c | + | ||||||||||
98a | + | + | |||||||||
98c | + | + | + | ||||||||
99a | + | + | + | ||||||||
99c | + | + | + | ||||||||
100a | + | + | |||||||||
100c | + | + |
Human serum samples were obtained from individuals with invasive episodes of S. aureus infection in Finland in 1999 and 2000. Patients had infections with or without deep infection foci, including abscesses, spondylitis, amnionitis, foreign body infections, pneumonia, and purulent arthritis. Sera were obtained 2 to 7 days after the first positive blood culture (a, acute phase) and 20 to 30 days postinfection (c, convalescent phase).
+, positive reactivity.